Z-VAD-FMK

Catalog No.S7023

Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.

Price Stock Quantity  
USD 117 In stock
USD 470 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Z-VAD-FMK Chemical Structure

Z-VAD-FMK Chemical Structure
Molecular Weight: 467.49

Validation & Quality Control

2 customer reviews :

Quality Control & MSDS

Product Information

  • Compare Caspase Inhibitors & Activators
    Compare Caspase Products
  • Research Area

Product Description

Biological Activity

Description Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.
Targets Pan-caspase [1]
(THP.1, Jurkat T-cells)
In vitro Z-VAD-FMK (10 mM) inhibits apoptosis in THP.1 cells. Z-VAD-FMK (10 μM) inhibits activation of PARP protease activity in control THP.1 cell lysates. Z-VAD-FMK (10 mM) inhibits the processing of CPP32 in intact THP.1 and Jurkat cells. [1] Z-VAD-FMK (50 μM) cotreatment abolishes the apoptotic morphology of camptothecin-treated HL60 cells. Z-VAD-FMK (50 μM) blocks camptothecin-induced DNA fragmentation in HL60 cells. [2] Z-VAD-FMK (50 μM) inhibits cell death following dSMN dsRNA-induced apoptosis in S2 cells. Z-VAD-FMK (50 μM) increases the percentage of transfected cells surviving from 26% to 63% in S2 cells. [3] Z-VAD-FMK (> 100 μM) enhances TNFα-induced neutrophil apoptosis, lower concentrations (1-30 μM) completely blocks TNFα-stimulated apoptosis in human neutrophils. [4] Z-VAD-FMK (10 mM) inhibits apoptosis in anterior stromal keratocytes. Z-VAD-FMK (10 mM) inhibits apoptosis in anterior stromal keratocytes detected with the TUNEL assay. [5]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
GC1aM2jDb2Fxd3C2b4Ppd{BCe3OjeR?=NFm4N442OM7:TR?=MUWyOIg>NHXKeHRqdmSrY3H0[ZMh[SCycn;0[YN1cX[nIHXm[oVkfCCjZ3HpcpN1KGW2b4Dvd4ll\Q>?NGfwOXMzPjF4OUC3OS=>
HGL5MlPPRZBweHSxc3nzJGF{e2G7M2HtTlUx|ryPM{PETFI1cA>?NVf2TYFjcW6maXPheIV{KGFicILveIVkfGm4ZTDl[oZm[3RiYXfhbY5{fCCndH;wc5Nq\GV?NV7VWodCOjZzNkmwO|U>
HepG2NV\aO3d{SXCxcITvd4l{KEG|c3H5M1q5XFIx|ryPNX7Wbld2OWh?M2rOdIF1fGWwdXH0[YQhfGinIHHwc5B1d3SrYzDpcoR2[3Srb36gc4YhUUmLLUGwxsA>NXfCb3UyOjZzNkS3PVU>
BEL-7402MoXURZBweHSxc3nzJGF{e2G7NF;JRXkzOM7:TR?=NWrHTGhUOWh?MXTheJRmdnWjdHXkJJRp\SCjcH;weI91cWNiaX7keYN1cW:wIH;mJGlKUS1zMNMgMmj0NlYyPjR5OUW=
CEFNHflTFhMcW6jc3WgRZN{[Xl?M4C3XFAtOzNuNkesNVAx|ryPNFnFcIYyPW2rbh?=NFT4OXdld3ewLYLl[5Vt[XSnczDQVkBmdnq7bXWgZYN1cX[rdImgeI8hPDExvJWgZZQhOTByzszNMXWyOlExOjN|OR?=
SP2/0NXS4NIRCSXCxcITvd4l{KEG|c3H5NFnEeGsyODEQvF2=NYHPUZV2OWh?Moq1SG1UVw>?MV7icI9kc3NidHjlJIFxd3C2b4Ppd{Bw\iCVUEKvNEBk\Wyucx?=M1zMNFI3ODd2N{Oy
HUVEC-2cNIe0VXFCeG:ydH;zbZMhSXO|YYm=MXK1NO69VQ>?M1vwTlZpMXTk[YNz\WG|ZXSgeIhmKG:6LVzEUE1qdmS3Y3XkJIF2fG:yaHHnfS=>MX:yOlAzOTd{OR?=
U1NWXn[pV[SXCxcITvd4l{KEG|c3H5NHuzcYoxNTFyMN88US=>MWSybC=>MUPy[YR2[2W|IHTyeYcucW6mdXPl[EBieG:ydH;zbZMh[W6mIIP1ZpNmeXWnboSgTGlXNTFicnXwcIlk[XSrb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=M2O5[|I2QThyOUSy
ACH-2NHvGN4pCeG:ydH;zbZMhSXO|YYm=M4K3ZVAuOjByzszNNYjUNG9tOmh?MlvxdoVlfWOnczDkdpVoNWmwZIXj[YQh[XCxcITvd4l{KGGwZDDzeYJ{\XG3ZX70JGhKXi1zIILldIxq[2G2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyMoSzNlU6QDB7NEK=
U1NGCzPG9McW6jc3WgRZN{[Xl?NIXoc|QyODEQvF2=MUWybC=>MkXpbY5pcWKrdIOgZ4F{eGG|ZT2zMUiyOVk5ODl2Mh?=
A549/V16M{DMOGFxd3C2b4Ppd{BCe3OjeR?=MUe1NO69VQ>?NVr4[3p{OWh?NFXxXllz\XC{ZYPz[ZMhXEdxVF2tbY5lfWOnZDDhdI9xfG:|aYO=MWGyOVk1PjB|Mx?=
SGNMkXVRZBweHSxc3nzJGF{e2G7M3;Hd|IxdU1?M{nVb|Q5cA>?MmTsbIF{KG6xIHnu[ox2\W6lZTDvckBCUUZuIHPhcJBicW5iZYjwdoV{e2mxbjDvdkBk\WyuIHHwc5B1d3Orcx?=M4Dw[VI2QDd2NkOz
HCT116 MmrzRZBweHSxc3nzJGF{e2G7Mor1OVDPxE1?MWiybC=>NG[0PXVqdmirYnn0d{B1cGViY3XscEBl\WG2aDDpcoR2[2WmIHL5JGRFXlB?MonvNlU5Pjh6MUi=
DTK-SMEM{C4OmFxd3C2b4Ppd{BCe3OjeR?=MWi1NO69VQ>?NGXZNIIzcA>?NWPGUXlETE2VTx?=NWfRbZBoeGG{dHnhcIx6KGmwaHnibZR{KHSqZTDhdI9xfG:|aYOgbY5lfWOnZDDifUBjfXCrdnHjZYlv\Q>?MonBNlU5PDN6OUe=
HL-60MnLaRZBweHSxc3nzJGF{e2G7NY\PepFzPTEQvF2=MVe0PIg>NFO4T5Fz\WS3Y3XzJINmdGxiZHXheIgh[2G3c3XkJIJ6KFONST3JTUB1emWjdH3lcpTDqA>?M4Did|I2QDJ2MESz
U937NUHV[4RqSXCxcITvd4l{KEG|c3H5NHLscpY2OM7:TR?=M{izZlQ5cA>?MYPy[YR2[2W|IHPlcIwh\GWjdHigZ4F2e2WmIHL5JHNMUS2LSTD0doVifG2nboVCpC=>MUKyOVgzPDB2Mx?=
A549NWnoNFZnSXCxcITvd4l{KEG|c3H5NFXoVVIzOCEQvF2=NXyx[lVDOjSqM4fYVJJm\HWlZYOgZ4VtdCCmZXH0bEBk[XW|ZXSgZpkhUE[FUDD0doVifG2nboS=MX[yOVc6PDF2OR?=
HeLaM{WwS2Fxd3C2b4Ppd{BCe3OjeR?=NELEU2MyOM7:TR?=NHLGbmM1QGh?NWG5U5lT\GWlbHnu[ZMhfGinIILheIUhd2ZiYYDvdJRwe2m|IHTyZY1ifGmlYXzsfS=>MmPoNlU4PzJ3NEW=
SGC-7901MnjXRZBweHSxc3nzJGF{e2G7NYKweXhiOjEEoN88US=>NUP0OJh[OWh?M{DEOIlvcGmkaYTzJJRp\SClZXzsJIRm[XSqIHnu[JVk\WRiYomgc5hidGmybHH0bY4>MV6yOVc3PzB5Nh?=
MCF-7Mo\iRZBweHSxc3nzJGF{e2G7M2PUcVEx|ryPNXHWO|l6Omh?NFfNWHRqdmirYnn0d{B1cGViY3XscEBl\WG2aDDpcoR2[2WmIHL5JFNDNEHNTHIzPTd{MkGxOC=>
A549M3;uOmFxd3C2b4Ppd{BCe3OjeR?=M3X5N|ExKM7:TR?=NWH3[IxUOjSqMYrEUXNQNIrHOolxem:vb4Tld{BJSkNvdILlZZRm\CCDNUS5JINmdGxic4Xyeol3[WxiJjDheJRmdnWjdHXzJJRp\SClbHXheoVlKFCDUmCg[ZhxemW|c3nvci=>NF:w[VUzPTZ6M{W2PC=>
U87NFW2dI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYi1NO69VQ>?NF3rO20ycA>?MV\y[YNwfmW{czDj[YxtKGe{b4f0bEBnem:vIGTNXkB1emWjdH3lcpQ>NX;tboZWOjV4OEG2Olg>
Neocortical NeuronMoDKUoV2em:2b4jpZ4l1gSCDc4PhfS=>Moq1NVAx|ryPNIP3NpAycA>?M3vyV4FvfGGpb37pfoV{KEixaXHtbYRmKEFvSX7keYNm\CCQZYXyc5RwgGmlaYT5MmXxNlU3PzVyMEG=
Primary human placental cytotrophoblastsM4D6WGFxd3C2b4Ppd{BCe3OjeR?=MWSzNO69VQ>?MXiyOIg>MoPNSG1UVw>?MYXy[ZZmenOnczD0bIUhcW6qaXLpeIlwdiCxZjCxNe6zNUiVREKgZpkhfHKrY3zvd4FvyqB?MoXwNlU3PDJ3OUK=
MMNXXTWGNGSXCxcITvd4l{KEG|c3H5MnfBOVDPxE1?M1PYV|IxdWmwMlrPdIFzfGy7IHnubIljcXS|IGPIT{1qdmS3Y3XkJEBk\WyuIHTlZZRpMnG4NlU2OzByOUi=
DLD1M3uyc2Fxd3C2b4Ppd{BCe3OjeR?=NVmyS4EzOjEEoN88US=>NH7Ob3cycA>?NFfzbIdx[XK2bImgdoV3\XK|ZYOgZ4VtdCCjcH;weI9{cXNiY3H1d4VlKGK7IGfTVFE>MmSyNlU2OjR{NE[=
MDA-MB-231MXzDfZRwfG:6aXPpeJkhSXO|YYm=NYOyTYxrOTEQvF2=MV6xbC=>M1i5[4F2\22nboTzJINmdGxiZHXheIgh[W[2ZYKgR2hWSSC2cnXheI1mdnR?MoDZNlU2OjF3MEG=
MKN28MWXBdI9xfG:|aYOgRZN{[Xl?M120bVEx|ryPMUKzNI1qdg>?M1i4NWROW09?M2TVXolvcGmkaYTzJHRPTi4QsTDwcJV{KEOKWD3pcoR2[2WmIHHwc5B1d3Orcx?=NWe5XYQ{OjV3MUO5OlA>
HL-60MojWR5l1d3SxeHnjbZR6KEG|c3H5MkLSNVAx|ryPMXKxbC=>NGHFcVVFVVORMUlCpIlueHKxdnXzJJZq[WKrbHn0fUBw\iCWQ17Bd{11emWjdHXkJINmdGy|MlXZNlU2ODJ7M{K=
AGSMXjBdI9xfG:|aYOgRZN{[Xl?MV6xNO69VQ>?NUn1V4JvOWh?NHzONmJxemW4ZX70d{BkfXKldX3pck1qdmS3Y3XkJINt\WG4YXflJI9nKGOjc4Dhd4UuOyxiLUisJIFv\CBvOTDwdo91\Wmwcx?=M2fvNVI2PDl{MkG0
A549 M{LLV2Fxd3C2b4Ppd{BCe3OjeR?=NVvubG5wOTEQvF2=MYqyOIg>MoPhZoxw[2u|IFTNRXMucW6mdXPl[EBkdGWjdnHn[UBw\iClYYPwZZNmNTNiYX7kJHBCWlBiYX7kJIFxd3C2b4TpZ{Bk\WyuIHTlZZRpNWH2NoExOjV2M{S5PFk>
INS-1MVHBdI9xfG:|aYOgRZN{[Xl?NWKyUoxpPTEQvF2=MVK2bC=>NIf2TpNFVVORMlvU[IVkemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJIViemy7IHHwc5B1d3SrYzDj[Yxte8LiNED5WWYzPTR|MEi5Oy=>
Primary hepatocytes NWnPRYJGSXCxcITvd4l{KEG|c3H5NI[zR|Q2OM7:TR?=NXLON2xVOTiqMXXpcohq[mm2czDhdI9xfG:|aYOgc4YhcGWyYYTvZ5l1\XNiaX7keYNm\CCkeTDBZ5QhTCCjbnSgWG5HNc7zMl;YNlU1ODd3M{i=
L929-A NF\i[GVEgXSxdH;4bYNqfHliQYPzZZk>MYqyNOKh|ryPMVeyOIg>M{HUXolvcGmkaYTzJHRPTs7zLXnu[JVk\WRiY3XscEBl\WG2aB?=MlraNlU{QTh3NEC=
L929-NMXXDfZRwfG:6aXPpeJkhSXO|YYm=M{DuUVIxyqEQvF2=MmHXNlRpM4faNIVvcGGwY3XzJIRm[XSqII\pZUBifXSxY4LpcoUhXE6IzsGgdJJw\HWldHnvci=>Mn;ONlU{QTh3NEC=
Cytotoxicity AssayM3XCXmNmdGxiVnnhZoltcXS7IFHzd4F6NGjtZpIzOM7:TR?=NYK5cFRlPDiqMoDJdJJmfmWwdDDNTG1FNWmwZIXj[YQh[2WubDDk[YF1cA>?MXKyOVM6OjFzNh?=
COS7MWPLbY5ie2ViQYPzZZk>NULsbXJCOTEQvF2=M3vOT|I1cA>?NUfHRmc4cW6lcnXhd4V{KGOjc4Dhd4UhOy95IHHjeIl3cXSrZYO=NGDLN5EzPTN6NECyOS=>
COS7MmXWRZBweHSxc3nzJGF{e2G7M1XZW|Ex|ryPMVK0PIg>NEDwc2tx[XK2aXHscJkheHKndnXueIVlKE[FMUCxMYlv\HWlZXSgZ4VtdCCmZXH0bC=>NEjUenAzPTN6NECyOS=>
A375MmnsRZBweHSxc3nzJGF{e2G7NXP1[Y44OzEQvF2=NIXGV5AzcA>?NE\iVplxemW4ZX70d{B1cGViZIL1[{1qdmS3Y3XkJHBCWlBiY3zlZZZi\2V?MUmyOVM4PjFzNR?=
A549MUTBdI9xfG:|aYOgRZN{[Xl?NYnnUIJ3PTEQvF2=NXHa[YtZOjSqMknodoV3\XK|ZYOgdoljd3OxbXWgZolw\2WwZYPpd{BidmRiYYDvdJRwe2m|IHPheZNm\CCkeTCgR4hqcm:wZ3Thci=>NUfyUFVJOjV|NEm3PFE>
A549NELRS5VCeG:ydH;zbZMhSXO|YYm=M4DqeVIvPS1{Nd88US=>NH7kd4EycA>?MojC[IVkemWjc3XzJJRp\SCyb4D1cIF1cW:wIH;mJIFxd3C2b4TpZ{Bk\WyuczDk[ZBmdmRib36gZ49v[2WwdILheIlwdnN?MXKyOVM1OjR{Nx?=
 NBL-W-S NGXobpBCeG:ydH;zbZMhSXO|YYm=NUDs[IxHPTEQvF2=MVmxbC=>NXrCTG5l\nWubImgdoV{[3WnczDj[YxtKH[rYXLpcIl1gSCjZoTldkBISU6WLU[xJJRz\WG2bXXueC=>NHvUVGUzPTN{M{KyNi=>
Caki-1 MkXQRZBweHSxc3nzJGF{e2G7NY[zTpdrPDEQvF2=NEDBS2s1QGh?NEPGV3Fz\WS3Y3XzJJRp\SCwdX3i[ZIhd2ZiQX7u[ZhqdiCYLYDvd4l1cX[nIHPlcIx{MlHsNlUzPzlzOUG=
769-PNF\OWIxCeG:ydH;zbZMhSXO|YYm=NXTUT4R3PDEQvF2=MWm0PIg>MXzy[YR2[2W|IITo[UBvfW2kZYKgc4YhSW6wZYjpckBXNXCxc3n0bZZmKGOnbHzzMUOyOVI4QTF7MR?=
H9c2M1G2TWFxd3C2b4Ppd{BCe3OjeR?=NFrV[IU2OM7:TR?=NIC2V5QycA>?NY\RfVlZcW6qaXLpeJMhTE:[LXnu[JVk\WRiY3HzdIF{\SB|IHHjeIl3[XSrb36gZpV1KG6xdDD0bIUhdG:|czDv[kBk\Wyucx?=MX:yOVI5OzhzOR?=
K562M3ruN2Fxd3C2b4Ppd{BCe3OjeR?=M3PTWFUx|ryPNYPpTGdlPGh?NFP5OXFqdmirYnn0d{BL[WNvQT3pcoR2[2WmIHPlcIwh[XCxcITvd4l{MViyOVI1OTZzOR?=
L929NXLKcXRjSXCxcITvd4l{KEG|c3H5NILLdWQyOM7:TR?=M2H1TlZpNYTocGlbcW6mdXPld{Bv\WO{b4D0c5NqeyC5aYToJHRPTg>?NILIUIUzPTF7NU[2NC=>
A549NYLGTo5rSXCxcITvd4l{KEG|c3H5MkjuNVDPxE1?MoLqN4g>NHe1c4Vz\WS3Y3XzJINmdGxiYYDvdJRwe2m|IHPheZNm\CCkeTDQVXE>NYS2ZXhWOjVzNkG2PVk>
MCF-7NXOxUYdISXCxcITvd4l{KEG|c3H5NFLVSYozOM7:TR?=MXKybC=>MVfk[YNz\WG|ZYOgT2RTNXOrUl7BMYlv\HWlZXSgZZBweHSxc3nzMmPKNlUyQDJ{NEC=
OSMVPBdI9xfG:|aYOgRZN{[Xl?MoHuNlAwPDEQvF2=M4XpW|czcA>?MlTEbY5pcWKrdIOgU3Mh[2WubDD2bYFjcWyrdImgdoVlfWO2aX;uJIJ6KEN4IHPldoFucWSnNYK2UJRVOjVzNUKzPVk>
HUVECsNHvOSpVCeG:ydH;zbZMhSXO|YYm=NYHmTm45OTEQvF2=NYjwSIt3Omh?MX5CpIlvcGmkaYTzJIFxd3C2b4Ppd{BidmRiZnHjbYxqfGG2ZYOgZZV1d3CqYXf5JIlvKESHTm[yMYlv\mWldHXkJGhWXkWFcx?=M{DHPVI2OTN6N{Cz
EA.hy926M3r0UWFxd3C2b4Ppd{BCe3OjeR?=Mn;TNVDPxE1?NWPrdYVbOmh?MnKxxsBqdmirYnn0d{BieG:ydH;zbZMh[W6mIH\hZ4ltcXSjdHXzJIF2fG:yaHHnfUBqdiCGRV7WNk1qdm[nY4Tl[EBGSS6qeUmyOi=>NHXve2IzPTF|OEewNy=>
EbsNFy0W|VCeG:ydH;zbZMhSXO|YYm=MVOxNE0yODEQvF2=NUXa[FRpOjSqM1j2NOKhVU2WUzDn[Y5memG2aX;uJJJifGViZHXjdoVie2WmIHHzJJRp\SClb37j[Y51emG2aX;uJI9nKHpvVlHEMoZucyCrbnPy[YF{\WR?MnfxNlUyOzR6MUe=
JurkatMoq0RZBweHSxc3nzJGF{e2G7NHnFXpUzOM7:TR?=NXrzSZg2OjSqM1XG[mROW09?MlzVdIFzfGmjbHz5JIlvcGmkaYSgZ4VtdCCmZXH0bEBw\iCMdYLrZZQh[2WubIOgbY5lfWOnZDDifUAyODB3OD3GOEBkd22kaX7l[EB4cXSqIG\QReKhM4\vOlI2OTJyN{Kz
K562NX\WOXZFSXCxcITvd4l{KEG|c3H5MVuwMlEuOc7:TR?=MWexbC=>MkTJbY5pcWKrdIOgZ4xm[X[jZ3Wgc4YhUFOSOUCgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=MUeyOVEyQTF6OB?=
IMR-32NY\nPFhGSXCxcITvd4l{KEG|c3H5MoXUOFDDqM7:TdMgNGDqc4MzcA>?NF6yWIZl\WO{ZXHz[UBqdiCjcH;weI91cWNiY3XscJMh[2:vcHHy[YQhfG9iVD2yJJRwgGmwMXWyOVA5PDd3NR?=
RPMI 8226NUCxO3JoSXCxcITvd4l{KEG|c3H5NHfDeXAyODEQvF2=MWOxbC=>MVnhcI1we3RiY3;tdIxmfGWueTDicI9kc3NiY3XscEBl\WG2aDDjZZV{\WRiYomgcoVkem:|dHH0bY4uOQ>?M3nrT|I2ODN5OEWx
U266 M1HDNGFxd3C2b4Ppd{BCe3OjeR?=NVz4[ZNJOTByzszNM2fIR|FpNV\xT2ZReGG{dHnhcIx6KGKub3Prd{Bk\WyuIHTlZZRpKGOjdYPl[EBjgSCwZXPyc5N1[XSrbj2xM1;OUFI2ODN5OEWx
H929 NXnY[mEzSXCxcITvd4l{KEG|c3H5MmOzNVAx|ryPNXzEOXI1OWh?M37PeZBienSrYXzsfUBjdG:la4OgZ4VtdCCmZXH0bEBk[XW|ZXSgZpkhdmWlcn;zeIF1cW5vMR?=MVqyOVA{Pzh3MR?=
MM.1S Mnv4RZBweHSxc3nzJGF{e2G7MUixNFDPxE1?M1vsZlFpM2TVXoVn\mmlaXXueIx6KHC{ZY\lcpR{KHOxcnHm[Y5q[i2rbnT1Z4VlKGOnbHyg[IVifGhiY3;tZolv\SC5aYToJI5m[3Kxc4TheIlvNTF?M3rjfVI2ODN5OEWx
C6M4XtOGFxd3C2b4Ppd{BCe3OjeR?=MlXsOVDPxE1?M{PkNFQ5cA>?NX\xXY9seHKndnXueJMhfGinIHzvd5Mhd2ZiY3XscEB3cWGkaXzpeJkh[2G3c3XkJIJ6KHC{ZXfu[Y5wdG:wZR?=MUeyOVAyOzR5OR?=
AGSMV\BdI9xfG:|aYOgRZN{[Xl?NIX5Zpg2OM7:TR?=M1HhN|I1cA>?MWjhZo9tcXOqczFOtk1t[XCjY3jvcoUucW6mdXPl[EBk\WyuIHTlZZRpKGGwZDDpcohq[mm2ZXSg[5Jwf3SqNIjKT3ozPTByOU[5PC=>
HeLa M3LUfWFxd3C2b4Ppd{BCe3OjeR?=MYS0NO69VQ>?M4\tTVI1cA>?NWLrdJFUcW6qaXLpeJMhfGinIHnuZ5Jm[XOnZDDhdI9xfG:|aYOgbY5lfWOnZDDifUB{cVKQRkGyNS=>MVOyOFkzQDZ6NR?=
THP-1 M{GzS2Fxd3C2b4Ppd{BCe3OjeR?=MWGxNO69VQ>?MVSxbC=>M4\IV5Jm\HWlZYOgZZBweHSxc3nzJIlv\HWlZXSgZpkhSUyDLWPEWOKhM4HsZVI1QTJ|NkWz
P815 NVTaTYRSSXCxcITvd4l{KEG|c3H5M4nRc|ExOCEEtV2=NIjFR2UyOmh?MnPSSG1UVw>?NVHufYpPcW6qaXLpeJMhfmm{dYOtbY5lfWOnZDDhdI9xfG:|aYO=MVSyOFkzOzJ5Mx?=
HCT116MVzBdI9xfG:|aYOgRZN{[Xl?NVrhSGN2OjEQvF2=M3TieVI1cA>?NYnzUIJi[WK{b3fheIV{KG:oIGTRMYlv\HWlZXSgZZBweHSxc3m=NE\QWYUzPDh7MES0PS=>
SW1116 MknYRZBweHSxc3nzJGF{e2G7MoLVNVAhyrWPM1rLWFFpNGPLbotFVVORMmrBdoV{fHKjaX7zJINmdGxiYYDvdJRwe2m|IHnu[JVk\WRiYomg[4VncXSrbnniJJBtfXNiZHXjbZRi[mmwZR?=MoTWNlQ5PzR{OE[=
LOVOMWDBdI9xfG:|aYOgRZN{[Xl?M3;lNVExKML3TR?=Mor0NYg>NF\5cGZFVVORM1[xUZJme3S{YXnud{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JIdm\mm2aX7pZkBxdHW|IHTlZ4l1[WKrbnW=MlrZNlQ5PzR{OE[=
SNU449 NW\DUmh{SXCxcITvd4l{KEG|c3H5M3f2VVIx|ryPNYDDeWpYPDiqMlq4SG1UVw>?MYPk[YNz\WG|ZYOgcYlTNTR3MT3pcoR2[2WmIHHwc5B1d3SrYx?=MUKyOFg1OTZ|OB?=
Caco-2Ml;4RZBweHSxc3nzJGF{e2G7NV:5Z5ptPDEkgJpOwG0>M4nHU|RpM3HZUJBz\X[nboTzJHNVNTdvaX7keYNm\CCcTz2xJINp[W6pZYOgZY5lKFSHUjDkdo9xNVrhOYRlOjR6MkKxPFM>
macrophageNVH1RnNJS2WubDDWbYFjcWyrdImgRZN{[Xl?M3fnNFAuOjByzszNMVuyOIg>NEf4WW9qdmS3Y3XzJHRPTi1iYX7kJHJqeDNvZHXw[Y5l\W62IH7lZ5JweHSxc3nzJIlvKG2jY4LvdIhi\2V?NXXKUZd[OjR5OUm1OlU>
AGS NYHTUVBTSXCxcITvd4l{KEG|c3H5MknxNlDPxE1?MY[xNog>NXXSNWZsTE2VTx?=Mk\ZdoVlfWOnczD0bIUhcW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBz\XOyb37z[UB1dyC2aHWgSZRQSWNiZoLhZ5Rqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?MkX1NlQ4QDl5MEO=
LCC9 M4ntd2NmdGxiVnnhZoltcXS7IFHzd4F6MXWxNFDPxE1?NFLlUoI2\A>?NIrlRohjdG:la4OgZ4VtdCCmZXH0bEBqdmS3Y3XkJIJ6KGOxbXLpcoF1cW:wIFyxO{BidmRiY3jsc5JweXWrbnW=M{XYZlI1Pzh3MkW2
U937 M1i1bo5m[3KxcITvd4l{KEG|c3H5MoS2NVDDqM7:TR?=MmnxN|DDqG2rbh?=MlrTbY5lfWOnczDu[YNzd3C2b4Ppd{Bkd22kaX7lJJdqfGhiVF7GMVqyOFc4Ozd3Nh?=
T cellM1zG[2NmdGxicILvcIln\XKjdHnvckBie3OjeR?=MWmwMVExOM7:TR?=M1zHWFczcA>?M4nGTWlEPTB;N{Cg{txONCCrbnjpZol1eyCjboTpMWNFOy2rbnT1Z4VlKFRiY3XscEBxem:uaX\ldoF1cW:wIHnuJHBDVUO|MojLNlQ4Pjh5MEe=
HeLa NV7DSIZNSXCxcITvd4l{KEG|c3H5MVS1NO69VQ>?NE\JNXU4Omh?NYG2fWhNTE2VTx?=NEXSbZRxemW4ZX70d{BieG:ydH;zbZMhcW6mdXPl[EBjgSClb33wc5Vv\HQEoEJihLM2NETiOVYzPDd3NEe4Oi=>
HeLa MoPzRZBweHSxc3nzJGF{e2G7MU[xNFDPxE1?NEO1Z2kzPGh?NULIOJF6e3WycILld5NmeyC{YYTlJI9nKGOnbHyg[IVifGhiaX7keYNm\CCkeTDveoVz\XiycnXzd4lwdiCxZjDHOVlUKG:{IFe3NXIheDF3MHfseYVlyqB?MYKyOFczOjR4OB?=
IEC-6 MlSyRZBweHSxc3nzJGF{e2G7MVWxNO69VQ>?M4HjUVI1cA>?M2fifZBz\X[nboTzJHRk\EFvaX7keYNm\CClYYPwZZNmNTNiY3zlZZZi\2ViYX7kJO6zNWOjdHXubY4h\GWpcnHkZZRqd25?M37seFI1PzFzNUex
HCT116MWXBdI9xfG:|aYOgRZN{[Xl?MmPZNlDPxE1?M{TMOlI1cA>?NYG4O4d2cW6qaXLpeJMhfGinIHPlcIwh[XCxcITveIlkKGmwZIXj[YQh[nliWVzUNlA2NFjsdWQzPDdzM{ixNi=>
L02MkLRRZBweHSxc3nzJGF{e2G7NGS5b|kzOM7:TR?=NV7scYk{OWh?MU\wdoV3\W62czD0bIUh[2WubDDhdI9xfG:|aYOgbY5lfWOnZDDifUBOTUiSNFHWUJozPDdyNkS2NS=>
A375MV3BdI9xfG:|aYOgRZN{[Xl?MV2yNO69VQ>?NUOw[3lQOjSqNX3qT45TemW4ZYLz[ZMh\GmlaYTybY5wdmViQj3pcoR2[2WmIHHwc5B1d3Orcx?=M3LmWFI1Pjl7MUGx
HDPCM13WNWFxd3C2b4Ppd{BCe3OjeR?=Moq0OVDDvU1?NIDjOlMzPGh?MXPpcohq[mm2czDOU{1qdmS3Y3XkJIFxd3C2b4Ppdy=>MUSyOFY{PDV7Mx?=
A549MmrTRZBweHSxc3nzJGF{e2G7M3rmVlUxyrWPMYOybC=>MlLPSG1UVw>?NXHKfIdueHKndnXueJMhfGinIHj5dI9lcXCub3nkJGRPSSClb370[Y51KHCqYYPlJIlv\HWlZXSgZpkh[2WyaHHsc4Npem:vaX6=NGDQcYMzPDV6OEGzOS=>
 BV-2MlyyRZBweHSxc3nzJGF{e2G7NV30fYs5OjEQvF2=MUSybC=>NVTudYt4e3WycILld5NmeyCXVj3pcoR2[2WmIHPodo9u[XSrbjDlfJRzfXOrb36gZY5lKGSrbHH0bY9vKG:oIITo[UBvfWOuZXHyJIVvfmWub4DlMUCyOFU2QDFzOB?=
HT-29 NUjRVGc3SXCxcITvd4l{KEG|c3H5NUX4enVrPTEQvF2=MY[0PIg>MnjsZoxw[2u|IITo[UBieG:ydH;zbZMhcW6mdXPl[EBjgSCtYXXtdIZmem:uNFm2[lIzPDV2OUG3OS=>
A549NWLnTmkxSXCxcITvd4l{KEG|c3H5NVe4TFJqPc7:TR?=NYm2dVE{OjSqNWPic2xUe3WycILld5NmeyB4ZdMgLGJMOTByNECpMYlv\HWlZXSgZZBweHSxc3nzxsA>NFf0WpAzPDV{OUi3NS=>
MIA-PaCa-2M3uzO2Fxd3C2b4Ppd{BCe3OjeR?=M1LaTVI1cA>?M3;CUIJtd2OtczDjcIVifmGpZTDv[kBk[XOyYYPlMVMhcW6mdXPl[EBjgSCkb4ToJGEuPDR|NkW0JIFv\CCyYXPsbZRigGWuNH[4U2YzPDVzMEm5Ni=>
Caki-1M2TIPWFxd3C2b4Ppd{BCe3OjeR?=NUfRcmVoOjEQvF2=M3HGbVFpMX;pcohq[mm2czDTR3AucW6mdXPl[EBieG:ydH;zbZM>M2XEUlI1PTB2Nkix
CLLM1r1VWFxd3C2b4Ppd{BCe3OjeR?=M3;pblI2|ryPM4KxbVFpNHnkbopx[XK2aXHscJkh[myxY3vzJG1NVjJ{M{itbY5lfWOnZDDj[YxtKGGyb4D0c5Nqew>?NHfFflQzPDR4N{[zOC=>
SGC-7901MXPBdI9xfG:|aYOgRZN{[Xl?M2Pyd|Ex|ryPNXLVbGhvOjSqMn3MdJJwdW:2ZYOgeIhmKEOJSVmtbY5pcWKrdHXkJINmdGxiZ4Lve5RpKGmwIGPHR{04QTBzIHPlcIx{NVG5UlV[OjR2NUS0PFg>
k1735NGLzdFFCeG:ydH;zbZMhSXO|YYm=NU\QNFVCOjEkgJpOwI0>M4fHXlRpMnnibY5pcWKrdIRCpHNidG2xbnXscIEucW6mdXPl[EBieG:ydH;zbZM>MknNNlQ1PTFzMU[=
HaCaT Mn;nRZBweHSxc3nzJGF{e2G7MUKxNFDPxE1?NULvWIZ2OWh?NUXIRoQ3[my3boTzJHVXSi2rbnT1Z4VlKGGyb4D0c5NqeyCrbjDIZWNiXCClZXzsdy=>NXy3T4dwOjR|NU[5PVc>
podocytesMoe4RZBweHSxc3nzJGF{e2G7NYPZcWpLOjByzszNM3v5XlZpM4\4[olvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KDNuND3ES2U>MUSyOFM{Pzd5Nx?=
 KBMXjBdI9xfG:|aYOgRZN{[Xl?MVi1NO69VQ>?NHTWUm4zPGh?M3;1W4lvcGmkaYTzJGxq[29vQT3pcoR2[2WmIHPhd5Bie2VvMzDhcoQhWEGUUDDhZ5RqfmG2aX;uM1T1fFI1OzN5NEmy
 HepG2 MofRRZBweHSxc3nzJGF{e2G7NEm2W2YyOM7:TR?=MnS1NlRpNFSyOFdz\WS3Y3XzJJZqdWWwdHnuJINt\WG4YXflJINifXOnZDDifUBNWFN?M1GxeVI1OzJ3OEG2
fetal rat lung fibroblasts NX7LbZJ4U2mwYYPlJGF{e2G7MWW4NO69VcLiMUGxbC=>M2LJ[olvcGmkaYTzJGNie3Cjc3WtN{Bi[3Srdnn0feKhM3XHb|I1OzF2MUO1
PDL fibroblastsM1vHR2tqdmG|ZTDBd5NigQ>?NWHSZWRiQDEQvF5CpC=>MXexbC=>MlXabY5pcWKrdIOgR4F{eGG|ZT2zJIFkfGm4aYT5xsA>MXOyOFMyPDF|NR?=
MB49MV3BdI9xfG:|aYOgRZN{[Xl?NUjEUmx{OjEQvF2=MWGxbC=>MXPy[ZZmenOnczDDUU1qdmS3Y3XkJINmdGxiZHXheIg>MWiyOFI5OjR|Mx?=
5637MnnBRZBweHSxc3nzJGF{e2G7NEmxNZozOM7:TR?=Mlj4NYg>NHTnZmhz\X[ncoPld{BEVS2rbnT1Z4VlKGOnbHyg[IVifGh?NE\2WYYzPDJ6MkSzNy=>
A549 NVTHVZBrSXCxcITvd4l{KEG|c3H5M3n0RlExOM7:TR?=NU\2R|ZUPDiqMXzzeZBxemW|c3XzJJRp\SCjcH;weI9{cXNiY3H1d4VlKGK7IIDpdIVzcW6nwrC=M3X2WVI1Ojd{MkCx
MCC-2NVX6OXIxSXCxcITvd4l{KEG|c3H5NFfUUWszOCEQvF2=MkXFOog>M4HlfmROW09?M1PmToJtd2OtczDpcoR2[2WmIHL5JJN1[XW{b4Pwc5JqdmViYYDvdJRwe2m|IHPlcIwh\GWjdHi=M2j4[|I1OjZ{NkW4
ADFNXv1ZoVPSXCxcITvd4l{KEG|c3H5M37IV|Qx|ryPNVTTWmlZPmh?NW\MN5M{cW6qaXLpeJMh[XCxcITvd4l{KGmwZIXj[YQh[nliY3jlcY91cGW{YYD5JJBtfXNiWn7DcFI>M1LOcVI1OjJ6MkOy
 U373 MXHBdI9xfG:|aYOgRZN{[Xl?NUHITmVGPDEQvF2=MoL5Oog>NE\1b29qdmirYnn0d{BieG:ydH;zbZMhcW6mdXPl[EBjgSClaHXtc5Rp\XKjcImgdIx2eyCcblPsNi=>NGq0RXgzPDJ{OEKzNi=>
RKO-HIPK2iMn[4RZBweHSxc3nzJGF{e2G7MoToOFDPxE1?NHvGXpc3cA>?NFz3c2RqdmirYnn0d{BieG:ydH;zbZMhcW6mdXPl[EBjgSClaHXtc5Rp\XKjcImgdIx2eyCcblPsNi=>MlnZNlQzOjh{M{K=
HEC-1BNU[5TJF2SXCxcITvd4l{KEG|c3H5NFvyTYkzOM7:TR?=MlPHNYg>NETVWG5z\WS3Y3XzJHRRNWmwZIXj[YQh[XCxcITvd4l{yqClYYPwZZNmNTNiYX7kJINie3Cjc3WtPS=>NUPFU2VGOjR{MUOzOVg>
4T1NFnuc2NE\WyuIG\pZYJqdGm2eTDBd5NigQ>?MorJNk42NTFyzszNM13MVVRpM3\pfmROW09?Mo\idoV{[3WnczD0bIUh[3m2b4TvfIlkcXS7IH;mJFRVOSClZXzsd{BqdmS3Y3XkJIJ6KFOSRGSgbY4h[SClb37j[Y51emG2aX;uJIRmeGWwZHXueEBu[W6wZYK=M4r6XlI1OjB4MU[x
OS NGj3PJVCeG:ydH;zbZMhSXO|YYm=NUDkbHBQOjEQvF2=MUK0bC=>M3;DSIlvcGmkaYTzJJRp\SClZXzsJIRm[XSqIHPheZNm\CCkeTDQSHQ>NYK4O5ROOjR{MES5N|c>
RPEMWnBdI9xfG:|aYOgRZN{[Xl?MkfSNVAx|ryPMYO0PIg>MYHwZZJ1cWGubImgbY5pcWKrdIOgeIhmKGOjbIDhbY4uOSCjbnSgMVIh[WO2aY\heIlwdiCjczD3[YxtKGG|IITo[UBk[XOyYYPlJIFkfGm4YYTpc44>NEn2N4czPDJyMkC1Ni=>
UD29aNESzS3NCeG:ydH;zbZMhSXO|YYm=NHrBN2Q2OM7:TR?=NH:zemwzPGh?MXfpcohq[mm2czD0bIUh[2WubDDk[YF1cCClYYXz[YQh[nliTmXUNy=>M2nOVlI1OTlyNUe0
SH-SY5Y NE[5N49CeG:ydH;zbZMhSXO|YYm=NXzpeVZZOTEQvF2=MXiyOIg>MmHUZZR1\W63YYTld{Bk[XOyYYPlJIFkfGm4YYTpc44h[W6mIHPlcIwh\GWjdHigbY5lfWOnZDDifUBJVkVvMlTHM1nNN|I1OTR3NE[z
HeLa MnrORZBweHSxc3nzJGF{e2G7NUfaUoxtOTBxMkFOwG0>NUPL[WxIOjSqMl7DbY5pcWKrdIOgeIhmKGGldHn2bZR6KG:oIITo[UBu[Wqxcnn0fUBw\iC2aHWgcYVu[mW{czDv[kB1cGViY3HzdIF{\S2oYX3pcJk>NF;jWXgzPDF|N{K2Oi=>
SCCVII MnvWRZBweHSxc3nzJGF{e2G7NFPKZnIzPc7:TR?=MYKxbC=>M2XtTYlvcGmkaYTzJJRp\SClZXzsJItqdGyrbnegZYZ1\XJiZHHzZZRqdmmkMX:yOFEzPjR4NB?=
RAW 264.7MnHzRZBweHSxc3nzJGF{e2G7MUeyNO69VQ>?NVzhNnpYOTiqNXTZb5gxcW6lcnXhd4V{KEyFMz3JTU/Pui2jY4TpckBz[XSrbzDjc41x[XKnZDD0c{BGS1SYLV3PV{B1emWjdH3lcpQhd26ueR?=NHHoPY4zPDFzNkewOy=>
A549 Mki1RZBweHSxc3nzJGF{e2G7NIPne3IzNjYQvF2=MWSyOIg>NG\US5pl\WO{ZXHz[ZMhd3KrZH;ubY4ucW6mdXPl[EBifXSxcHjh[5kh[XNid3XscEBidmRiTH;zd{Bw\iEQlN-IcUBidHOxIH;jZ5VzemWmIHT1dolv\yCjdYTvdIhi\2mlIIDyc4Nme3N?M4G3XVI1OTB{NUKy
UM-SCC-10A NUS0bY5WSXCxcITvd4l{KEG|c3H5MV61NOK2VQ>?MnHjNog>NHzCW3Zz\WS3Y3XzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KGirZ3it[I9{\SCrc3;hcIFvfG:uYXP0c45mNWf4VpVtOjRyOUi3OVM>
BGC-823NYT5O41ySXCxcITvd4l{KEG|c3H5MYSxNEDPxE1?NH7qWVIzPGh?MVHy[YR2[2W|IITleJJidmS{aX7lMYlv\HWlZXSgZZBweHSxc3nzxsA>NGrvdHczPDB7OEWxNS=>
Nalm-6 NGnnUYxCeG:ydH;zbZMhSXO|YYm=NIWybJIzOM7:TR?=MmrwOIg>M1q1VIlvcGmkaYTzJINie3Cjc3WtPEBidmRiY3HzdIF{\S1|IHHjeIl3[XSrb36gZY5lKFCDUmCtNUBkdGWjdnHn[S=>MnvxNlQxOzl7Nke=
KHOS MWrBdI9xfG:|aYOgRZN{[Xl?MkG1OFDPxE1?M17relI1cA>?M2naZYJtd2OtczD0bIUhcW6lcnXhd4VlKGOuZXH2ZYdmKG:oIHPhd5Bie2VvMzDhcoQhWEGUUDDpcoR2[2WmIHL5JGJDVUR|wrC=NEP4[WIzPDB{NUO2NS=>
G292M4PDS2Fxd3C2b4Ppd{BCe3OjeR?=NXTvUZdmPDEQvF2=NEP4UpkzPGh?MlTVZoxw[2u|IITo[UBqdmO{ZXHz[YQh[2ynYY\h[4Uhd2ZiY3HzdIF{\S1|IHHu[EBRSVKSIHnu[JVk\WRiYomgRmJOTDQEoB?=MXmyOFAzPTN4MR?=
MG-63NFvaOW9CeG:ydH;zbZMhSXO|YYm=MkTDOFDPxE1?NFPQZ3kzPGh?M1XIOoJtd2OtczD0bIUhcW6lcnXhd4VlKGOuZXH2ZYdmKG:oIHPhd5Bie2VvMzDhcoQhWEGUUDDpcoR2[2WmIHL5JGJDVUR|wrC=M3Ls[FI1ODJ3M{[x
EBV-transformed B cellsNWLjcIdJSXCxcITvd4l{KEG|c3H5MYmyNO69VQ>?MUmybC=>MVPEUXNQNWnlUI03[myxY3vzJIFvfGlvQ1S4NEBidmRiYX70bU1ETDh4IHHueIljd2S7LXnu[JVk\WRiYYDvdJRwe2m|MkfzNlQxODh4Mki=
IM-9 BM{f6[mFxd3C2b4Ppd{BCe3OjeR?=MVGyNO69VQ>?NIK1clUzcA>?NIL4dnZFVVORM3Ps[IJtd2OtczDhcpRqNUOGOECgZY5lKGGwdHmtR2Q5PiCjboTpZo9lgS2rbnT1Z4VlKGGyb4D0c5Nqew>?MYOyOFAxQDZ{OB?=
CNE1MX\BdI9xfG:|aYOgRZN{[Xl?MoK0NlDPxE1?M2XkXlQ5cA>?M1;pcIJtd2OtczDMT{1CNWmwZIXj[YQh[XCxcITvd4l{NGG1T4QzOzl6NUCyPS=>
CNE2Mn;zRZBweHSxc3nzJGF{e2G7NVrKSFd5OjEQvF2=NUHPSGtXPDiqMVTicI9kc3NiTFutRU1qdmS3Y3XkJIFxd3C2b4Ppdy=>MmHmNlM6QDVyMkm=
HL-60NUDLVotSSXCxcITvd4l{KEG|c3H5NF\4e5I2OML3TR?=NX3OcmlwOWh?NHvYUnVFVVORM{LUZ4lvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KEKDMUS1M{DqSFI{QTR6N{Wx
L929M3jzPWFxd3C2b4Ppd{BCe3OjeR?=NYXkbXc3OS5{NfMAl|XDqM7:TdMgNV7KN2ltOjSqM4XocIF2\22nboTzJHRPTs7zLXnu[JVk\WRibnXjdo9xfG:|aYOgZY5lKGG3dH;wbIFogQ>?M4m3eFI{QTRzN{[5
JurkatMUjD[YxtKF[rYXLpcIl1gSCDc4PhfS=>M2PhXVLPxE1?Mme5OIg>MXTy[ZZmenOnczDndo94fGhiaX7obYJqfGmxbjDhcoQh|rJvY3H0[Y5qdiCmZXPy[YF{\SCkeTDIV{1CW0F?NIHRd3UzOzh7NkC2NS=>
RAW264.7 MV\BdI9xfG:|aYOgRZN{[Xl?MmT6NVAh|ryPNGSxUJQzPGh?NGfRfZZl\WO{ZXHz[ZMhfGinIHHwc5B1d3OrczDpcoR2[2WmIHL5JGdCNYPqVY9tOjN6MkCyNFM>
A431 NYHDXo9pU2mwYYPlJGF{e2G7NYnXU2ZwPDEQvF2=MUKybC=>NFr3R4RjdG:la4Og[ol{\XSrbj3pcoR2[2WmIHPs[YF3[WenIH;mJINie3Cjc3XzJIFv\CCSQWLQMlrpNlM5ODByNUi=
JurkatNEHOU3dE\WyuIG\pZYJqdGm2eTDBd5NigQ>?M1nHOVI2NTFyMN88US=>NXvVe3llPmh?M{\jdIlvcGmkaYTzJJouTkFvQ13LMYlv\HWlZXSgZ4VtdCCmZXH0bC=>Mnn5NlM6OzN3M{K=
COS-7 MXHGeY5kfGmxbjDBd5NigQ>?NIDYRVI2OML3TR?=MWeyOIg>MkfOZYZn\WO2czD0bIUheHKxY3Xzd4lv\yCxZjDBWG4yeyC5aYToJJBwdHmTIITyZYN1ew>?MY[yN|k{OzJyOB?=
CAL27MlzwRZBweHSxc3nzJGF{e2G7MXGxNEDPxE1?NVLQWFlCOmh?M{nRWZN2eHC{ZYPz[ZMhS3W{LV7Qd{1z\WS3Y3XkJJZq[WKrbHn0fUBjgSC3cDD0c{A6OCV?NIK3eYwzOzlzN{O5Oi=>
THP-1 NGLSbWFCeG:ydH;zbZMhSXO|YYm=M2TROVExNTVyzszNNF3Hc2czcA>?NUm0Nng1cW6qaXLpeJMh[XCxcITvd4l{KGmwZIXj[YQh[nlidILpdJRwdGmmZR?=NFjiZZMzOzlyMEK5PS=>
K562MWDBdI9xfG:|aYOgRZN{[Xl?MU[yNO69VQ>?MkKxOFhpNIGxO|VqdmirYnn0d{BieG:ydH;zbZMhcW6mdXPl[EBjgSB2LV3VM3;BT|I{QDd4OEK2
HL-60M3;OWmFxd3C2b4Ppd{BCe3OjeR?=NX\1N3NuOTByzszNNGTtXnczPGh?Ml;1bY5pcWKrdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkh[WKrZYThcoUh\Gm2ZYLw[Y5me8LiMn:4NlM5PjV5N{i=
HeLa M{DlZWFxd3C2b4Ppd{BCe3OjeR?=MXGyNO69VQ>?MkPmNog>Ml7SbY5pcWKrdIOgSG1OWCCrbnT1Z4VlKGGyb4D0c5Nqew>?NHvmSYMzOzh4M{m2Oi=>
U251M1\HeWFxd3C2b4Ppd{BCe3OjeR?=M2PGSVIx|ryPMof1NlRpNFnoS4FqdmirYnn0d{Bk[XO2aXPpckBqdmS3Y3XkJGczN01icHjhd4Uh[XK{ZYP0JIFv\CCjcH;weI9{cXN?MlvDNlM5OTZ6MU[=
HL-60Mo\rRZBweHSxc3nzJGF{e2G7NIXicYk2OML3TR?=Mln2OIg>M{\wUYJtd2OtczD0bIUh[2ynYY\h[4Uhd2ZiY3HzdIF{\S1|LDCtPUwh[W6mIGDBVnAhcW6mdXPl[EBjgSB4cx?=NIW0NoIzOzhyNEewOi=>
Ec-109MYPBdI9xfG:|aYOgRZN{[Xl?M3LnblExKM7:TR?=Mom1OFhpMUTy[ZBz\XO|ZYOgVGUudWWmaXH0[YQhTWNvMUC5JINmdGxiYYDvdJRwe2m|MkHTNlM4QDJ4NEG=
RKOM4fY[GNmdGxiVnnhZoltcXS7IFHzd4F6M4n0SFExKM7:TR?=NXPNR3dJOjSqMmKwbY5pcWKrdIOgeIhmKGSnY4LlZZNmKG:oIHPlcIwhfmmjYnnsbZR6KGOjdYPl[EBjgSCGQVK=M1vobFI{PzV6ME[0
T98GMV;D[YxtKF[rYXLpcIl1gSCDc4PhfS=>MojwNU0yODEQvF2=MX6yOIg>MWrpcZBzd3[nczDj[YxtKH[rYXLpcIl1gSClb4Ty[YF1dWWwdDD3bZRpKFSVNHT5e3YzOzd4OUK3OS=>
JurkatMXrD[YxtKF[rYXLpcIl1gSCDc4PhfS=>MVixNFAuOjByzszNMkHzNlRpNX;qbXM{cW6qaXLpeJMhUGGDNDDpcoR2[2W|IHHwc5B1d3OrczDk[ZBmdmSnboSgc4Yh[2:wY3XueJJifGmxbtMgM3L6O|I{PzN{NEix
Molt-3 MmT0RZBweHSxc3nzJGF{e2G7MmHrOVDPxE1?NF;Jfm0zcA>?MUDy[YR2[2W|IH3lcIF1d26rbj3pcoR2[2WmIHHwc5B1d3Orcx?=NHrsRYgzOzd{NUCxNy=>
hMSC12NHu5NpNCeG:ydH;zbZMhSXO|YYm=MXexNFDPxE1?NXHYRWNzPGR?M4fwS4lvcGmkaYTzJI9{fGWxZ3XubYMh[3WudIXy[U1qdmS3Y3XkJINmdGxiZHXheIgh[W6mIHPhcINq\mmlYYTpc44>M4q4dVI{PjV5OEKy
HM7 MmXMRZBweHSxc3nzJGF{e2G7Mn\sNlDPxE4EoB?=M1TuZ|FpNH;FdXpjdG:la4OgZZBq[3WuYYLlckBCKGGlZYTheIUucW6mdXPl[EBk[XOyYYPlMVMh[WO2aY\heIlwdiCjbnSgVGFTWCClbHXheoFo\Q>?MWeyN|U5OzRzMh?=
Hep-2 NF\FVnpCeG:ydH;zbZMhSXO|YYm=MojnNlDPxE4EoB?=NEW2W|MzPGh?MYnEUXNQM{nVd4FtdGW4aXH0[ZMhfGinIHTlZ5Jm[XOnIH;mJINmdGxidnnhZoltcXS7IHnu[JVk\WRiYomgd4ltcWKrbnnuNWPXeFFJOjN3OECwN|I>
HSCsM4O5[WFxd3C2b4Ppd{BCe3OjeR?=MXW1NO69VQ>?MV2yOIg>NWDEXGN7TE2VTx?=NI\Ke|NqdmirYnn0d{BvcWyxdHnubYIucW6mdXPl[EBFVkFiZHHtZYdmKGmwZHnjZZRm\CCkeTDQRXJRKGOuZXH2ZYdmNYfjdotPOjN2OUm4O|Q>
HL-60 NHv1XlVEgXSxdH;4bYNqfHliQYPzZZk>NVe5ZZV1OjEQvF5CpC=>M3zpVFI1cA>?M2DSd5Jm\HWlZYOgeIhmKGO7dH;0c5hq[yCnZn\lZ5Qhd2ZiRYL5OS=>MVqyN|Q6PDR6MB?=
HANGf6dXlCeG:ydH;zbZMhSXO|YYm=MWe1NO69VQ>?MnzpNlRpMWTzeZBxemW|c3XzJJRp\SClbHXheoFo\SCxZjDQRXJRKGGwZDDjZZNx[XOnLUOsJE04NCCjbnSgMVkhcW6mdXPl[EBjgSCkb4L0[ZpwdWmkL2PBTGE>NF;n[lYzOzR5NUm1Oi=>
C666-1NGDiUGJCeG:ydH;zbZMhSXO|YYm=MVS1NO69VQ>?MUWyOIg>MoXQd5VxeHKnc4Pld{B1cGViY3zlZZZi\2Vib3[gVGFTWCCjbnSgZ4F{eGG|ZT2zMEAuPyxiYX7kJE06KGmwZIXj[YQh[nliYn;yeIV7d22rYj;TRWhCMUGyN|Q4PTl3Nh?=
Hepa1-6MXjBdI9xfG:|aYOgRZN{[Xl?NEfmOII2OM7:TR?=MnTZNog>MkK5bY5pcWKrdIOgZ5Vz[3WvaX6gZY5lKHKnc4\ldoF1em:uLXnu[JVk\WRiYYDvdJRwe2m|NFfyeY8zOzR2Nke1Ny=>
PLC/PRF/5cNHrOTI5CeG:ydH;zbZMhSXO|YYm=MUO1NO69VQ>?MlXGNYg>NFflXW1xemW4ZX70d{BieG:ydH;zbZMhfHKrZ3fldoVlKGK7IFPJUi=>NWn3XZpWOjN2M{i4NlQ>
HCT116MmXSRZBweHSxc3nzJGF{e2G7M4r1ZVExOM7:TR?=M4fmflEvPWh?NEnQcHJqdmirYnn0d{BQey2rbnT1Z4VlKGOnbHyg[IVifGh?MlL0NlM4PDR|NUO=
HCECMkXGSpVv[3Srb36gRZN{[Xl?NUTD[VVYPTEQvF2=NYnsOmdDPzKqMYnEUXNQMlfrdoV{fG:{ZYOgc4YhfGinIH7vdo1idCCKQ1XDJJBp\W6xdInw[S=>M4f4OlI{PzR{MEGx
Primary rat cerebral cortical neuronsNFvLZYlCeG:ydH;zbZMhSXO|YYm=MUKxNFDPxE1?NHHEWYgycA>?M4nVbZBz\X[nboTzJGNlNWmwZIXj[YQh[XCxcITvd4l{KGGwZDDj[YxtKGSnYYToNV[zblRlOjN5NEGzNVc>
MDA-MB-231 MXHBdI9xfG:|aYOgRZN{[Xl?NH;TPWgzPc7:TR?=Ml;CNlRpNIi5[o5i[nKxZ3H0[ZMh[3m2b4TvfIlkcXS7IHHu[EBkdGWjdnHn[UBw\iClYYPwZZNmNTNiYX7kJHBCWlBiaX7keYNm\CCkeTDS[|M>M4iwdFI2OzN5NUS0
NLRP3-Tet-on-MC/9 NEPBR4lCeG:ydH;zbZMhSXO|YYm=M2PQRVExNTRyzszNNHLRfJgyOmh?NF21[2difHSnboXheIV{KHSqZTDj[YxtKGSnYYToJINifXOnZDDifUBESVCVLXHzd49kcWG2ZXSgUmxTWDNibYX0ZY51eyCrbjD0bIUhXGW2LX;uJJN6e3SnbR?=NV7WTWJFOjN5MEOzPFk>
KNS42 MorzRZBweHSxc3nzJGF{e2G7MXm1NO69VQ>?MWmxbC=>M2OyTZJm\HWlZYOgZ4VtdCCmZXH0bEBidmRiY3;tdIxmfGWueTDhZo9tcXOqZXSgZ4F{eGG|ZTCzM|ch[WO2aY\peJkhcW5icnXzdI9ve2VidH:gRWJVNTJ4Mz:ySGcwdWW2Zn;ycYlvKGOxbXLpcoF1cW:wNG\pTpYzOzZ7MUG0OS=>
MCF-7 MWDBdI9xfG:|aYOgRZN{[Xl?MYGyNO69VcLiM4L0RVczcA>?MVXpcohq[mm2czDldZVwdC1iYX7kJFQuV0iWLX3l[IlifGWmIHHwc5B1d3Orcx?=M1zu[FI{Pjd3NkSz
hCMEC/D3 NFSxXIpCeG:ydH;zbZMhSXO|YYm=NV7BfG9zOjYQvF2=NEXO[Jc4Omh?MkLHdoVlfWOnczDMeJhCKGmwZIXj[YQh[XCxcITvd4l{MYiyN|Y3PTF7OB?=
JurkatM3fuPWFxd3C2b4Ppd{BCe3OjeR?=NEiz[20yOi53LUWw{txOMkfyNYg>MYjkc5NmKGSncHXu[IVvfGy7IIP1dJBz\XO|ZYOgV3BJNWmwZIXj[YQhWGG{LUSgZ4xm[X[jZ3WsJHBCWlBiY3zlZZZi\2VuIFTORUBnemGpbXXueIF1cW:wLDDhcoQhdG:|czDv[kB3cWGkaXzpeJk>MYWyN|Q1Ojl5Nh?=
CNE-1NH7RNZNCeG:ydH;zbZMhSXO|YYm=MnfSNlDPxE4EoB?=MkHhNlRpMULpcohq[mm2czDSRWQxODFvaX7keYNm\CClZXzsJIRm[XSqM2nUc|I{PDJ4OEWw
HONE-1MW\BdI9xfG:|aYOgRZN{[Xl?NFX3e4EzOM7:TdMgM1:xelI1cA>?NH7JZ5lqdmirYnn0d{BTSURyMEGtbY5lfWOnZDDj[YxtKGSnYYToM2HVZlI{PDJ4OEWw
astrocytes cellMlziRZBweHSxc3nzJGF{e2G7NFfvU2Q1OM7:TR?=NFnOcY03cA>?NVXOb25XemWmdXPld{Bm[XKueTDhdI9xfG:|aYOgbY5lfWOnZDDifUB{fGG3cn;zdI9zcW6nMUCyN|QyOTd5OB?=
U-937MoPvRZBweHSxc3nzJGF{e2G7MYqxNO69VQ>?MU[zNI1qdg>?NYPaSIhmeHKndnXueJMhXE6ILXnu[JVk\WRibnXjdo9xfG:|aYO=MXWyN|QyODd2OB?=
MDA-MB-231NHiwSXBCeG:ydH;zbZMhSXO|YYm=NHH5[oUyODEQvF2=MYqxbC=>Ml;LbY5pcWKrdIOgd4Vve2m2aYrheIlwdiC2bzDUVmFKVCC3cH;uJG1VTEhiZH;3ck1z\We3bHH0bY9vMX[yN|QxQDR{OR?=
HeLa M3;PeGFxd3C2b4Ppd{BCe3OjeR?=NVjXPI1ROTByzszNNV72dFN1Omh?NWG5[mox[myxY3vzJGpTWy1zNTDJcoR2[2W|IFHwc5B1d3SrYzDD[YxtKESnYYToNFjVWGozOzN2NEC0OS=>
Ec109MYrBdI9xfG:|aYOgRZN{[Xl?MVOxNO69VQ>?M{LIZVZpNYnDPXF[[myxY3vzJIFxd3C2b4TpZ{Bkd22kaX7heIlwdiCxZjDUZZQuW22jY163JIFv\CC{YXTpZZRqd25?Mn[yNlM{Ozh3Nki=
H460 NIDz[I1CeG:ydH;zbZMhSXO|YYm=MVuxNO69VQ>?MXe2bC=>MmTyZoxw[2u|IHHwc5B1d3SrYzDjc41jcW6jdHnvckBw\iCWYYStV41i[055IHHu[EBz[WSrYYTpc44>NF\ReogzOzN|OEW2PC=>
HeLa M173PWFxd3C2b4Ppd{BCe3OjeR?=M{TpTlUx|ryPMUOxMlVpNHX4Z4di[nKxZ3H0[ZPDqEOqbHHtfYRq[S2rbnT1Z4VlKGGyb4D0c5Nqew>?NFW3NYUzOzNyM{iwOC=>
SK-HEP1MX;BdI9xfG:|aYOgRZN{[Xl?Mm\qNVAx|ryPNXXyWlhWOWh?NGjCS3dqdmirYnn0d{BEelRzIHHjeIl3[XSnZDDjZZNx[XOnLUOsJE04NCBvODygMVktKGGwZDDwc4x6MEGGUD3ybYJwe2VrIIDvcJlu\XKjc3W=NWnUSphEOjN|MEK2OVA>
QGY7701NUPx[lB{SXCxcITvd4l{KEG|c3H5M1X3O|I2|ryPMXSxMlVpMlfmbY5pcWKrdIOgZYNkfW23bHH0bY9vKG:oIIP1Zk1IOSCyaHHz[UBqdmS3Y3XkJIJ6KESRWDCrJJF2\XKlZYTpci=>M{LpbFI{OjRyME[x
HepG2M4L4VWFxd3C2b4Ppd{BCe3OjeR?=M4PPN|Ix|ryPMUCzNI1qdg>?M3HLSIlvcGmkaYTzJJRp\SCnbnjhcoNm\CClZXzsJIRm[XSqIHL5JINwdWKrbnXkJJRz\WG2bXXueEBw\iCjcHnn[Y5qdiCjbnSgWHJCUUx?NGP3S2EzOzJ{NEKzPS=>
U87 MYTBdI9xfG:|aYOgRZN{[Xl?NVjncFRiOjYQvF2=MW[ybC=>NWP2NFJk\GWlcnXhd4V{KGm|b3zpdZVqemm2aXflcolvKCiLU1ypMYlv\HWlZXSgZZBweHSxdHnjJINmdGxiZHXheIgtKGK3dDDuc5QhdmWlcn;0bYMh[2WubDDk[YF1cA>?MnP2NlMzOjl4Mk[=
HSC-2MU\BdI9xfG:|aYOgRZN{[Xl?NVrW[XlDOjVxNUFOwG0>MojpNYg>MVfpcohq[mm2czDTUk0{QC2rbnT1Z4VlKGO7dH;0c5hq[2m2eR?=M4PXO|I{OTV3MkS4
HSC-4MVPBdI9xfG:|aYOgRZN{[Xl?MkK4NlUwPTEQvF2=MWGxbC=>MWrpcohq[mm2czDTUk0{QC2rbnT1Z4VlKGO7dH;0c5hq[2m2eR?=MV6yN|E2PTJ2OB?=
CL-1NGPRflRCeG:ydH;zbZMhSXO|YYm=NVPWOpJPOjEQvF2=MX:xbC=>NVfaV4hF[myxY3vzJG9RPDR7IHnu[JVk\WRiY3XscEBl\WG2aB?=MmXGNlMyOzF5OEK=
MELNXzJNIdDSXCxcITvd4l{KEG|c3H5MWCyNO69VQ>?MoO5NlRpNHjEdJBFVVORMVjpcZBicXKnczDQNng4NWmwZIXj[YQhVUWOIHPlcIwh[XCxcITvd4l{NYP5SmhqOjNyMUS4PFc>
Bel-7402 M3HscGNie3Cjc3WgRYN1cX[jdHnvckBCe3OjeR?=NVf1O2FFPTEQvF2=NV23[VdSOmh?M3[1eIlvcGmkaYTzJHBETS2rbnT1Z4VlKGGwb3nrbZM>MmjtNlMxODh5NEK=
Eca-109NYi4NFNmSXCxcITvd4l{KEG|c3H5NVi0O2lzOjYQvF2=NFf4Upo{OG2rbh?=MWHpcohq[mm2czDCTk1DOTFvaX7keYNm\CClZXzsJIRm[XSqM2PZd|I{ODd4OU[3
MELNGTLZ2tCeG:ydH;zbZMhSXO|YYm=MY[yNO69VQ>?MlTTNYg>MYXEUXNQNFLQPHZqdXCjaYLld{BROlh5LXnu[JVk\WRiTVXMJINmdGxiYYDvdJRwe2m|Ml61NlMxOTR6OEe=
Bel-7402 MVrBdI9xfG:|aYOgRZN{[Xl?NXrHelBIPTEQvF2=Mo[2Nog>NEHKbFZqdmirYnn0d{BRS0VvaX7keYNm\CCjbn;pb4l{NWrqSlJ1OjNyMEi3OFI>
L929MkfCSpVv[3Srb36gRZN{[Xl?NVrPb4t2Oi53zszNMVOxbC=>NVrFbJRscW6lcnXhd4V{KFKLUEGg[ZhxemW|c3nvckBidmRiZYjhZ4Vz[mG2ZXSgWG5H|rFvaX7keYNm\CCvaYTvZ4hwdmS{aXHsJIR6e2[3bnP0bY9vKGGwZDDSU3MheHKxZIXjeIlwdg>?NVLVeZNxOjNyMEC1NVg>
RCC MljhR4VtdCCYaXHibYxqfHliQYPzZZk>NF23clcyODEQvF2=NYjlcWF[OjSqNGC2[IVz\WOxdnXy[ZMhfGinII\pZYJqdGm2eTDv[kBk\WyuczDlfJBwe2WmIITvJFE2\C2SR1qyNXLPXlE4OjJ7OUG0PVQ>
NB2a/d1NUXKSG5RSXCxcITvd4l{KEG|c3H5M2H5VlExOM7:TR?=M4rUSFczcA>?NUHhdItD[XS2ZX71ZZRmeyC|dHH1do9{eG:{aX7lMYlv\HWlZXSgZ4F{eGG|ZTDhZ5Rqfmm2eTygVGFTWCxiYX7kJJRifSClbHXheoFo\Q>?NH;V[2IzOjl6OEW0NS=>
T cellMXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M17RcFI2NTFyMN88US=>NVrRPFJDOjSqM3SzSoRwe2VvZHXw[Y5l\W62bImgbY5pcWKrdHXkJHQh[2WubDDwdo9tcW[ncnH0bY9vKG2nZHnheIVlKHSqcn;1[4ghfGinIHPvMZN1cW23bHH0bY9vKHerdHigZY51cS2FREOgZY5lKGGwdHmtR2QzQA>?MlvFNlI6QDJ3M{i=
K562MVXBdI9xfG:|aYOgRZN{[Xl?NV\QUWtQOTByzszNMlTMNYg>NEOyOFRjdG:la4OgRYJvd2KjdnnzZ5VuyqCILXnu[JVk\WRiYYDvdJRwe2m|NXi4S5V2OjJ7N{KzO|I>
Jurkat NFn1ZYdCeG:ydH;zbZMhSXO|YYm=NWTtV4c6PDEQvF2=NXPvNIQ5OWh?M4TjSYFjd2yrc3jld{BH[XOOLXnu[JVk\WRiY3HzdIF{\SCjY4TpeoF1cW:wIHHu[EBk\WyuIHTlZZRpNG\Fd5EzOjl2MkezPC=>
BGC-823NVnsWGxOSXCxcITvd4l{KEG|c3H5MmfZNVAx|ryPM162UVFpM3\YdZBienSrYXzsfUBz\XOldXXzJINmdGy|IHHnZYlve3RiZHHtZYdmKG:oIHThbYR7\WmwNIW5bHMzOjl{NkW0OS=>
Hep3BNUfmdVlnSXCxcITvd4l{KEG|c3H5MVS1NO69VQ>?NF\iT3kycA>?MoPCZoxw[2u|IHHwc5B1d3OrczDpcoR2[2WmIHL5JGhGT0O|NH\5N5gzOjl{M{G1OC=>
LLC-PK1NHvHXJZCeG:ydH;zbZMhSXO|YYm=MnSxNlDPxE1?NGTjXmEycA>?MWHwdoV3\W62czDjbZNxdGG2aX6tbY5lfWOnZDDk[Ydz[WSjdHnvckBw\iCDdHe1MEBj\WOuaX6tNUwh[W6mIFH0[|EzKHC{b4TlbY5{NUnnNIx1OjJ6OU[wN|c>
A549NIrvZ4FCeG:ydH;zbZMhSXO|YYm=M333V|Ux|ryPMn\INYg>NEXVRoJjdG:la4OgeIhmKEKDST3pcoR2[2WmIHHwc5B1d3Orc9MgNWK2eopYOjJ6OEeyNVU>
SGC-7901 NVfJWZhVSXCxcITvd4l{KEG|c3H5NHXLd4UyOM7:TR?=MWOyOIg>MmnLbY5pcWKrdIOg{tIt|rJvZHnt[ZRpgWyjY4L5cJNpcWuxbnnuMYlv\HWlZXSgZZBweHSxc3nzxsA>MlHaNlI5PDh3OUe=
DM6NH7CWGJCeG:ydH;zbZMhSXO|YYm=NVTBS4x{OTByzszNNYPjWYhZPzKqM{PvVoJtd2OtczDic5RpKEV{Rj2xJIFv\CCHMl\0dk1u\WSrYYTl[EBkgXSxdH;4bYNqfHl?M1;PPFIzQDJ3M{K4
MCF-7, MDA-MB-468, Caco-2M4XaSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn;VOVDPxE1?NETMUZc1QGh?NVT2UldFcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJIlvcGmkaYTpc44hcW6mdXPl[EBjgSC|YYDvcolvNGjtSYgzOjhyMEm2PC=>
A2750 MYDBdI9xfG:|aYOgRZN{[Xl?NFvzfJczOM7:TR?=MVSybC=>MUHEUXNQMXTicI9kc3NiY3HzdIF{\SClbHXheoFo\SCmdYLpcochcGWuZX7hcIlvKHS{ZXH0cYVvfCCjbnSgdoVlfWOnczDheZRweGijZ3njJINmdGxiZHXheIg>NEHMdVQzOjd6NEO2Ny=>
U87 Mmj6RZBweHSxc3nzJGF{e2G7NYDoWYVtOjEQvF2=NHfUSG0zPGh?M1;qT5Jm\HWlZYOgeIhmKGGyb4D0c5NqeyC{YYTlJIlv\HWlZXSgZpkhWEyDQh?=MWCyNlc4QDd6MB?=
HT1080NUf4b5ZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYS1NO69VQ>?MWm3[C=>M3fsSIlvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDpcohq[mm2aX;uJINifXOnZDDifUBkd22kaX7l[EB1emWjdH3lcpQhd2ZiRFPBJIFv\CCRTWC=NWm5U2pXOjJ5NEC5PFQ>
A549 NUHxUXJTSXCxcITvd4l{KEG|c3H5Mn\5OVDPxE1?MXSybC=>NFzHNnJx[XK2aXHscJkh\GWlcnXhd4V{KHOxZHn1cUB{\Wynbnn0[U1qdmS3Y3XkJIFxd3C2b4Ppdy=>NYXHO4dVOjJ5MkG4NFQ>
Primary OPCNHvaNGlCeG:ydH;zbZMhSXO|YYm=NV7CUlVyOc7:TR?=NF32fZA3cC9{NHi=MlOwdoVlfWOnczD0bIUheGW{Y3XueIFo\SCxZjDj[YxteyCrbjDlZZJtgS1iYX7kJIxifGVvYYDvdJRwe2m|L37lZ5Jwe2m|NWjReHA4OjJ5MEezPFU>
PMNsMlzHRZBweHSxc3nzJGF{e2G7NUHrNJhVPDEQvF2=MljXOog>MlvjSG1UVw>?NVzHO4c6emW4ZYLz[YQhfGinIHHtc5VvfCCxZjDjcIVifmWmIHPhd5Bie2VvMzD0c{Bv\WG{II\lbIlkdGVibHX2[Yx{MoXVNlI3QTJ3N{e=
A549 NVP3NoFqSXCxcITvd4l{KEG|c3H5NUfqVldHPTEQvF2=NHvvWFAycA>?M3XKNJBz\X[nboTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KEKjb3j1c5Nq\GViSR?=MmH6NlI3QDd4M{W=
AGSNX;XWVBUSXCxcITvd4l{KEG|c3H5M2jUZlIx|ryPMWexNog>M{PkfolvcGmkaYTzJJRp\SCjY4TpeoF1cW:wIH;mJJBzdy2lYYPwZZNmNTNiaX6gdoV{eG:wc3WgeI8hfGinIFX0U2FkKG[{YXP0bY9vM2jm[FIzPjh5M{m4
shC9 NYm3dXp7SXCxcITvd4l{KEG|c3H5MUmxNO69VQ>?NV[0fYF3OT[qM{j4U4JtfW62czDTTGgh\XiycnXzd4lwdiCrbjDzbGM6KGOnbHzzJIV5eG:|ZXSgeI8h\Wm2aHXyJHBCKG:{IFzQRy=>MXKyNlY1OTB7NB?=
primary MEFsMnHJSpVv[3Srb36gRZN{[Xl?NWDibFBDOTKqNXfpWpVyyqCrbnPy[YF{\XNiZYTvdI9{cWSnLXnu[JVk\WRibXn0c4Npd26mcnnhcEBu\W2kcnHu[UBl\XCxbHHybZpifGmxbh?=M{TsU|IzPjF|N{[3
3T9 MEFsNETPS5JHfW6ldHnvckBCe3OjeR?=NXXxdpR5OT[qNIn0epZqdmO{ZXHz[ZMh[3m2b3Podo9u\SClIILlcIVie2ViYX\0[ZIh\XSxcH;zbYRmNXS{ZXH0cYVvfA>?NXywOodMOjJ4MUO3Olc>
3T9 MEFsM37xUGZ2dmO2aX;uJGF{e2G7MoflNVhpMYn1dJJm\3WuYYTld{Bqdmm2aXH0c5Ih[2G|cHHz[U06KGK3dDDkc5dvemWpdXzheIV{KGWoZnXjeI9zKGOjc4Dhd4V{KGGodHXyJIV1d3Cxc3nk[UB1emWjdH3lcpQ>M1f0bVIzPjF|N{[3
MDA-MB-231 M2fqdWFxd3C2b4Ppd{BCe3OjeR?=MkDSNlDPxE1?M{HDfFRlNIHJ[JJz\WS3Y3XzJJRp\SClZXzsJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KG2ndH\vdo1qdiC2cnXheI1mdnRid3HzJJNq\26rZnnjZY51dHl?NXHPfnQ{OjJ3OUO0OFE>
C6 NXf4fGc{SXCxcITvd4l{KEG|c3H5NV\xPFl1OTEQvF2=M2\UelI1cA>?Mm\4Zoxw[2u|IITo[UB{fXCycnXzd4l3\SCnZn\lZ5Qhd2ZidHjlJJBmeHSrZHWgc44hfmmjYnnsbZR6NUnhUWxUOjJ3OEi5PFA>
HL-60 NG\qWGxCeG:ydH;zbZMhSXO|YYm=M4m3OFExOM7:TR?=M2PPdlI1cA>?MlvSbY5pcWKrdIOgeIhmKGOnbHygZZBweHSxc3nzJJNmdGWldHXkJEgsMS2vZX70bJltKM7{LTix5qaTPilvZHnncJVkd3C7cnHuc5Nq\GYEoEW=MWOyNlU1PjZ4OR?=
HL-60M{nyd2Fxd3C2b4Ppd{BCe3OjeR?=NVLkN4VJOTBvOEFOwG0>MmPQOIg>NX64fW5VcW6qaXLpeJMhXEeKUT3pcoR2[2WmIHPlcIwh[XCxcITvd4l{yqB?NELudJUzOjV{M{KyPS=>
BCCM4exfGFxd3C2b4Ppd{BCe3OjeR?=M3fQVVUx|ryPMWKxbC=>NEjNNYdqdmirYnn0d{BFSVSVLX3l[IlifGWmIHfyc5d1cCCrbnjpZol1cW:wNF7lWYczOjVzOUSzOi=>
RAW 264.7NXH2TFFwSXCxcITvd4l{KEG|c3H5NYLMeYJRPTBxMUCw{txOMmTHNYg>M3KwV4NwdmOnboTyZZRqd25vZHXw[Y5l\W62IHnubIljcXS|IFTPUk1qdmS3Y3XkJJJTVkFiY3zlZZZi\2V?M1XyPVIzPDlzNEK2
K562M2fvd2Fxd3C2b4Ppd{BCe3OjeR?=M{jKXFI2|ryPNYrpZYExOmh?NWnsPIdMeHKndnXueJMh[XCxcITvd4l{KGmwZIXj[YQh[nliY3:teJJm[XSvZX70JJdqfGhiYX31doVve2mwIFegZY5lKFSUQVnMMUiyNlQ5Ozd5Nx?=
SGC-7901MnG2RZBweHSxc3nzJGF{e2G7MlLNNlAh|ryPwrC=MonYNog>M3P5doF1fGWwdXH0[ZMhUDKRMtMgc5IhXE6IIN8xMYlv\HWlZXSgZ4VtdCCjcH;weI9{cXNiYYOge4VtdCCjczDjZZNx[XOnLUOgZYN1cX[rdIpCpC=>NVTN[|NDOjJ2N{G1PFk>
PC3NYLmcI5kSXCxcITvd4l{KEG|c3H5NWjaSZJEOTEQvF2=MWK0bC=>M362SYNwfW62ZYLzJIZt[X[xY3;4bYQucW6mdXPl[EBk[XOyYYPlMZJmdGG2ZXSgZZBweHSxc3nzMV6yNlQ4OTl5NB?=
SMMC-7721Mn65RZBweHSxc3nzJGF{e2G7NVWweG5sPTEQvF2=NU\3OXA4PDiqMUTheJRmdnWjdHXzJI9VWi2rbnT1Z4VlKGGyb4D0c5Nqew>?NIHCXFMzOjR4NUizNy=>
HeLa NXXPNGo2SXCxcITvd4l{KEG|c3H5MY[1NOKh|ryPMoPJOE85cA>?MnHxbY5pcWKrdIOgV3RUNWmwZIXj[YQhdGG2ZT3wbIF{\SCjcH;weI91cWNiZY\lcpR{NEHFPVQzOjR4MEWwOC=>
HeLa NGLoR4VCeG:ydH;zbZMhSXO|YYm=M3ewZlUxyqEQvF2=M4ToWFFpMXjzeZBxemW|c3XzJJRp\SCIUlHQMYlv\HWlZXSgZYNkfW23bHH0bY9vKG:oIHHucoV5cW5iVjDwc5NqfGm4ZTDj[Yxtew>?NF:wdWkzOjR2OUS0NC=>
T47D NXTjepdMSXCxcITvd4l{KEG|c3H5MnfnNVAx|ryPMkDxNYg>NF7JSJFjdG:la4OgeIhmKGenbnXyZZRqd25ib3[gSU1k[WRxQ2TGNkBjgSCVVGO=MV[yNlQxOTF4OB?=
HeLa MYfBdI9xfG:|aYOgRZN{[Xl?MX:zNO69VQ>?NEW2PFQ1cA>?NFXEUo7DqGmwY4LlZZNmeyC2aHWg[4Vv\XKjbDDj[YxtKH[rYXLpcIl1gSB2ODDoJIFnfGW{IIDoc5Rw\HmwYX3pZ{B1emWjdH3lcpTDqA>?M2PiN|IzOzl2MkS4
HCCNF3OclVCeG:ydH;zbZMhSXO|YYm=MUmyNEDPxE4EoB?=NUfRWZBsOmh?MmrCZZR1\W63YYTld{B1cGViRFjBJIlv\HWlZXSgZYN1cX[jdHnvckBw\iCSQWLQMoX2NlI{PDJ5M{K=
mESCsNIfyS|RCeG:ydH;zbZMhSXO|YYm=NWC5XVV3Oi53zszNNHXUPJczcA>?NVjDd5NqcW6qaXLpeJMhfGinIF7hSk1u\WSrYYTl[EBk[XOyYYPlJIFkfGm4YYTpc44>M1zC[lIzOjh3Mke0
EMT-6 MVHDfZRwfG:6aXPpeJkhSXO|YYm=NH;q[JQyODEQvF2=NVnQc5plOWh?NWSx[lNTeGG{dHnhcIx6KGKub3Pr[YQh[2WubDDk[YF1cCCrbnT1Z4VlKGK7IIPpdoFu\XOrbnW=M3ThfVIzOjVzOUKx
MCF7M{jWRWFxd3C2b4Ppd{BCe3OjeR?=NYXSXFBxPTEEoN88US=>NF3mZVQycA>?MmrUbY5pcWKrdIOgVGEh[WO2aY\heIVlKGOjc4Dhd4UuOyxiLUmsJIFv\CCyb3z5LGFFWC2{aXLvd4UqKHCxbInt[ZJie2V?MYCyNlIzOzN2NR?=
K562M3HlR2Fxd3C2b4Ppd{BCe3OjeR?=M2n0TFIxKM7:TdMgMn3iOFhpNIWxTHpFVVORNX\sOWxC[myxY3vzJIxieGG2aX7pZk1qdmS3Y3XkJIlvcGmkaYTpc44hd2ZidnnhZoltcXS7IHHu[EBieG:ydH;zbZMhcW6mdXP0bY9vMoLYNlIzOTZzNUi=
Molt4-hygNHrxOVZCeG:ydH;zbZMhSXO|YYm=NXO5WmZxOTEQvF2=MoPNNE42cA>?NIXtbodjdG:la4Og[oFzdmW|b3ytbY5lfWOnZDDjZZNx[XOnLUOtcIls\SCjY4Tpeol1gQ>?NH3uZZczPjJ5NUixNS=>
HeLaMkP5RZBweHSxc3nzJGF{e2G7MY[xNO69VQ>?MlzVNE42cA>?NYrqcIFOcW6qaXLpeJMh[XCxcITvd4l{KGmwZIXj[YQh[nlidHjlJINwdWKrbnXkJJRz\WG2bXXueEB4cXSqIHfvcYl{cW5iTjDhcoQhXFKDSVy=NFy5N3MzOjF5OU[2NS=>
Jurkat TNHPiOXVCeG:ydH;zbZMhSXO|YYm=NWnZWZFFOzEQvF2=MofHNE42cA>?MWTEUXNQM1vPcYJtd2OtczD0bIUhgmm{YX2tbY5lfWOnZDDhdI9xfG:|aYO=MUGyNlE2QTh7OB?=
NeutrophilM{Trc2Fxd3C2b4Ppd{BCe3OjeR?=M2HTW|Ix|ryPMUmwMlVpM2\pT4F1fGWwdXH0[ZMhfGinIIDyc{1ieG:ydH;0bYMh\W[oZXP0JI9nKE2jUkG=M1u4RVI3OTl4OES0
HCT116NHPUS5hCeG:ydH;zbZMhSXO|YYm=M{H1flUxyqEQvF2=MWGybC=>NEfFZYVz\X[ncoPld{B{gW6ncnfpd5Rq[yCjcH;weI9{cXNiZX\m[YN1eyCxZjDj[Yxm[2:6aXKgZY5lKE6SQz2xOuKhNWPndVZlOjJzNUm3OVI>
MDA-MB-231 NYrNS41ZSXCxcITvd4l{KEG|c3H5MWSyMlUuPy53zszNM1ztblJpNUW1VYdCcW6qaXLpeJMhfGinIHPlcIwh\GWjdHigc4YhVUSDLV3CMVI{OSClZXzsd{BqdmS3Y3XkJIJ6KFOGVDDpckBiKGOxbnPlcpRz[XSrb36g[IVx\W6mZX70JI1idm6nch?=NXjQPZM5OjJzMUW1NlY>
LNCaPM2jBN2Fxd3C2b4Ppd{BCe3OjeR?=MYG0NO69VQ>?NX2ybZNmOmh?MW\pcohq[mm2czDieZRmcW5iaX7keYNm\CClZXzsJIFxd3C2b4Ppdy=>Ml;LNlIyOTR5NkS=
MB231MmXDRZBweHSxc3nzJGF{e2G7NEj1WmoyODEQvF2=MXWxbC=>NYLQb2l6TE2VTx?=MU\hZpJw\2G2ZYOgeIhmKGmwZIXjeIlwdiCxZjDj[YxtKGSnYYToJIJ6KFeHRUGgbY5pcWKrdHnvckwhXFKDSVygeJJm[XSvZX70MEBidmRidHjlJINwdWKrbnH0bY9vNInHdlczOjFzMkm0NC=>
HCC38 MUnBdI9xfG:|aYOgRZN{[Xl?MXexNFDPxE1?MWGxbC=>NFPaN5hFVVORMU\hZpJw\2G2ZYOgeIhmKGmwZIXjeIlwdiCxZjDj[YxtKGSnYYToJIJ6KFeHRUGgbY5pcWKrdHnvckwhXFKDSVygeJJm[XSvZX70MEBidmRidHjlJINwdWKrbnH0bY9vM4Hn[VIzOTF{OUSw
MDA-MB231M{i5eGFxd3C2b4Ppd{BCe3OjeR?=MVW1NOKh|ryPNEn2To0zPGh?NELi[XNFVVORM{fuPYFjem:pYYTld{BkfXKldX3pck1qdmS3Y3XkJINmdGxiZHXheIg>M1zVZlIzOTBzM{O1
LNCaPM1njRmFxd3C2b4Ppd{BCe3OjeR?=M{XnT|UxyqEQvF2=MVyyOIg>NHqybodFVVORMniwZYJzd2ejdHXzJIN2emO3bXnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=>NHXBWZUzOjFyMUOzOS=>
HCT116MlrsRZBweHSxc3nzJGF{e2G7MUS1NOKh|ryPMXKyOIg>MXLEUXNQMnrEZYJzd2ejdHXzJIN2emO3bXnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=>MUWyNlExOTN|NR?=
Ishikawa MUXBdI9xfG:|aYOgRZN{[Xl?NIPwcpczPc7:TR?=M{PmWVI1cA>?NH3DcI5z\WS3Y3XzJINmdGxiZHXheIgh[W6mIHHwc5B1d3OrczDpcoR2[2WmIHL5JGJi\iCDMR?=NWLQcXp{OjJyOEi5NVg>
 YD-8 NXHEc3ZJSXCxcITvd4l{KEG|c3H5M3K4WFExOM7:TR?=NGLLOY4ycA>?MYXpcohq[mm2czDQUGVQNWmwZIXj[YQh[XCxcITvd4l{MXyyNlA5PjF6Mx?=
eosinophil NG[4SoRCeG:ydH;zbZMhSXO|YYm=M1O3OFkx|ryPNYDxRlI3OjSqNVjsfJY3cW6qaXLpeJMh[XCxcITvd4l{KGmwZIXj[YQh[nliRnHzJIFvfGmkb3T5xsA>NGDHfGozOjB5OUOzOC=>
L929NVLNSWN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mm\SNk42|ryPNEDaeIkzPGh?NF7GR5ZqdmirYnn0d{B1cGViZYjwdoV{e2mxbjDv[kBxNXB|ODDhcoQhVkZvzsrCJJRwKGG3Z33lcpQhXE6IzsGtbY5lfWOnZDDu[YNzd3C2b4Ppd{BidmRiYYX0c5Bp[We7Mn[zNlIxOjdyOUe=
YD-8 MYHBdI9xfG:|aYOgRZN{[Xl?MWCxNFDPxE1?MUixbC=>NYezVIFU[myxY3vzJJRp\SCJUz3IR4wucW6mdXPl[EBieG:ydH;zbZM>NIrsOXYzOjB{MEC3PC=>
HBxM12yR2Fxd3C2b4Ppd{BCe3OjeR?=NYL2PFJFOjYQvF2=NXnEfJZ{PDiqMXnEUXNQNX2zeJZSemWmdXPl[EBk\WyuIHTlZZRpKGmwZIXj[YQh[nliMz3NRS=>MWiyNlAzODB5OB?=
U937 Mnu5RZBweHSxc3nzJGF{e2G7NGPaOFE2OMLizszNNUnOZVQ{OWh?NXPpU2RrcW6qaXLpeJMhUEZvaX7keYNm\CCjcH;weI9{cXQEoB?=MXWyNVk6QDd|MR?=
HL60M4fXfGFxd3C2b4Ppd{BCe3OjeR?=NHjDb|U1OM7:TR?=NVzhRoNGPDCvaX6=NFvyfnBFVVORMWTicI9kc3NiQl7ER{Bkd22yb4Xu[JMhcW6mdXPlJIV5eG:|dYLlJI9nKHCqb4PwbIF1cWS7bIPldolv\SCjbnSgSG5CKG[{YXft[Y51[XSrb36=MX:yNVk5OzJ7Nh?=
M-14MmOwRZBweHSxc3nzJGF{e2G7Mn3nNlXPxE1?NWn3T3lvOC53aB?=NGPGWnbDqGmwaHnibZR{KGKxdHigeIhmKGO{dXTlJIV5fHKjY4StJIFv\CClb33wc5Vv\C2rbnT1Z4VlKGGyb4D0c5Nqew>?MWSyNVk2PDl3OR?=
SK-BR-3M4\sO2Fxd3C2b4Ppd{BCe3OjeR?=NVr6Nm5iPTEEoN88US=>NVT5epZFOmh?M2K4VYJtd2OtczDhdI9xfG:2aXOgSG5CKG[{YXft[Y51[XSrb36gbY5lfWOnZDDifUBkd22kaX7heIlwdiCxZjDTUU0yPjRiYX7kJJJi\GmjdHnvci=>NFPle|gzOTlyMUO4Oi=>
MDA-MB-468NV\Wc3FjSXCxcITvd4l{KEG|c3H5NFq4NmY2OMLizszNMlvjNog>NGrqO|BjdG:la4OgZZBweHSxdHnjJGRPSSCocnHncYVvfGG2aX;uJIlv\HWlZXSgZpkh[2:vYnnuZZRqd25ib3[gV20uOTZ2IHHu[EBz[WSrYYTpc44>M4r3T|IyQTBzM{i2

... Click to View More Cell Line Experimental Data

In vivo
Features A key compound for apoptosis studies.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Slee EA, et al. Biochem J, 1996, 315 (Pt 1), 21-24.

[2] Shimizu T, et al. Leukemia, 1997, 11(8), 1238-1244.

view more

Chemical Information

Download Z-VAD-FMK SDF
Molecular Weight (MW) 467.49
Formula

C22H30FN3O7

CAS No. 187389-52-2
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 93 mg/mL (198 mM)
Water <1 mg/mL (<1 mM)
Ethanol 24 mg/mL warming (51 mM)
DMF 84 mg/mL
* Z-VAD-FMK will racemize in DMSO, water and ethanol.
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name L-Alaninamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-3-fluoro-1-(2-methoxy-2-oxoethyl)-2-oxopropyl]-

Customer Product Validation(2)


Click to enlarge
Rating
Source Acta Pharmacol Sin 2014 35(4):531-9. Z-VAD-FMK purchased from Selleck
Method Western blot
Cell Lines SaOS2 human osteosarcoma cells
Concentrations 10 uM
Incubation Time 24 h
Results To investigate the effect of the caspase inhibitor zVAD-fmk on the icaritin-induced apoptosis, it performed Western blot analysis to evaluate the levels of cleaved caspase-3. It found that the caspase inhibitor zVAD-fmk could decrease the icaritin-induced caspase-3 expression in the zVAD-fmk+icaritin-treated group compared to the icaritin-treated group (P<0.05).

Click to enlarge
Rating
Source Med Oncol, 2015, 32(4): 538 . Z-VAD-FMK purchased from Selleck
Method Western Blot
Cell Lines Gastrocnemius muscles
Concentrations 1.5 mg/kg
Incubation Time 5、12 days
Results Results from western blot analyses showed that ATF2 levels were higher in the tumor-bearing animals than in the healthy controls. ATF2 levels in the groups treated with CFZ, z-VAD-fmk, or CFZ + z-VAD-fmk, at either 5 or 12 days after inoculation, were lower than in the CC group (treated with PBS).

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Caspase Products

  • MI-773 (SAR405838)

    MI-773 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1.

  • A-1210477

    A-1210477 is a potent and selective MCL-1 inhibitor with Ki and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.

  • Belnacasan (VX-765)

    Belnacasan (VX-765) is a potent and selective inhibitor of caspase-1 with Ki of 0.8 nM in a cell-free assay. Phase 2.

    Features:A potent and selective inhibitor of interleukin-converting enzyme/caspase-1.

  • PAC-1

    PAC-1 is a potent procaspase-3 activator with EC50 of 0.22 μM and the first small molecule known to directly activate procaspase-3 to caspase-3.

    Features:The first small molecule known to directly activate procaspase-3 to caspase-3.

  • Apoptosis Activator 2

    Apoptosis Activator 2 strongly induces caspase-3 activation, PARP cleavage, and DNA fragmentation which leads to the destruction of cells (Apaf-1 dependent) with IC50 of ~4 μM, inactive to HMEC, PREC, or MCF-10A cells.

  • Tasisulam

    Tasisulam is an antitumor agent and an apoptosis inducer via the intrinsic pathway. Phase 3.

  • ABT-263 (Navitoclax)

    ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

  • Venetoclax (ABT-199, GDC-0199)

    Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with Ki of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 3.

    Features:Re-engineered version of ABT-263 (Navitoclax).

Recently Viewed Items

Tags: buy Z-VAD-FMK | Z-VAD-FMK supplier | purchase Z-VAD-FMK | Z-VAD-FMK cost | Z-VAD-FMK manufacturer | order Z-VAD-FMK | Z-VAD-FMK distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us